<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36280624</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Factors predicting disease progression in C9ORF72 ALS patients.</ArticleTitle><Pagination><StartPage>877</StartPage><EndPage>890</EndPage><MedlinePgn>877-890</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11426-y</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To unveil clinical features, comorbidities, disease progression and prognostic factors in a population-based cohort of ALS patients carrying C9ORF72 expansion (C9&#x2009;+&#x2009;ALS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a retrospective observational study on ALS patients residing in Emilia Romagna and Piedmont-Valle D'Aosta regions whose data are available through population based registers. We analysed patients who underwent genetic testing, focusing on C9&#x2009;+&#x2009;ALS subgroup.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 2204 genotyped patients of the two registers, 150 were C9&#x2009;+&#x2009;ALS. In comparison with patients without mutation, a higher proportion of family history (12.85 vs 68%, p&#x2009;&lt;&#x2009;0.001) and frontotemporal dementia (3.93% vs 10.67%, p&#x2009;&lt;&#x2009;0.001) was detected in C9&#x2009;+&#x2009;ALS. C9&#x2009;+&#x2009;ALS presented a faster disease progression as measured by monthly decline in ALS Functional Rating Scale-Revised (1.86&#x2009;&#xb1;&#x2009;3.30 vs 1.45&#x2009;&#xb1;&#x2009;2.35, p&#x2009;&lt;&#x2009;0.01) and in forced vital capacity (5.90&#x2009;&#xb1;&#x2009;5.24 vs 2.97&#x2009;&#xb1;&#x2009;3.47, p&#x2009;&lt;&#x2009;0.01), a shorter diagnostic delay (8.93&#x2009;&#xb1;&#x2009;6.74 vs 12.68&#x2009;&#xb1;&#x2009;12.86&#xa0;months, p&#x2009;&lt;&#x2009;0.01) and earlier onset (58.91&#x2009;&#xb1;&#x2009;9.02 vs 65.04&#x2009;&#xb1;&#x2009;11.55&#xa0;years, p&#x2009;&lt;&#x2009;0.01). Consistently, they reached death or tracheostomy earlier than other patients (31 vs 37&#xa0;months, HR&#x2009;=&#x2009;1.52, 95% C.I. 1.27-1.82, p&#x2009;&lt;&#x2009;0.001). With respect to other genotyped patients, C9&#x2009;+&#x2009;ALS patients did not present a significantly higher prevalence of concomitant diseases. Independent prognostic factors of survival of C9&#x2009;+&#x2009;ALS included sex, age, progression rate, presence of frontotemporal dementia and thyroid disorders, with the latter being associated with prolonged ALS survival (43 vs 29&#xa0;months, HR&#x2009;=&#x2009;0.42, 95% C.I. 0.24-0.74, p&#x2009;=&#x2009;0.003).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Even in the context of a more aggressive disease, C9&#x2009;+&#x2009;ALS had a longer survival in presence of thyroid disorders. This finding may suggest protective pathogenic pathways in C9&#x2009;+&#x2009;ALS to be explored, looking for therapeutic strategies to slow disease course.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9244-9782</Identifier><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. jessica.mandrioli@unimore.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. jessica.mandrioli@unimore.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zucchi</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Experimental Medicine Ph.D. Program, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van der Most</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gianferrari</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solero</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, AOU Citt&#xe0; della Salute e della Scienza of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassano</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, AOU Citt&#xe0; della Salute e della Scienza of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunetti</LastName><ForeName>Maura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>SC Neurologia 1U, AOU Citt&#xe0; della Salute e della Scienza of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzini</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ALS Center, Neurology Unit, AOU Maggiore della Carit&#xe0; and University of Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marchi</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Center, Neurology Unit, AOU Maggiore della Carit&#xe0; and University of Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonini</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fini</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tupler</LastName><ForeName>Rossella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinceti</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Science of Public Health, Research Centre in Environmental, Genetic and Nutritional Epidemiology, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, AOU Citt&#xe0; della Salute e della Scienza of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, AOU Citt&#xe0; della Salute e della Scienza of Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF-2016-02362405</GrantID><Agency>Ministero della Salute</Agency><Country/></Grant><Grant><GrantID>259867</GrantID><Agency>Seventh Framework Programme</Agency><Country/></Grant><Grant><GrantID>2017SNW5MB</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>DEPARTMENT OF EXCELLENCE</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>AGING Project FOR DEPARTMENT OF EXCELLENCE</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>ALS-Care</GrantID><Agency>EU Joint Programme - Neurodegenerative Disease Research</Agency><Country/></Grant><Grant><GrantID>Strength</GrantID><Agency>EU Joint Programme - Neurodegenerative Disease Research</Agency><Country/></Grant><Grant><GrantID>Brain-Mend projects</GrantID><Agency>EU Joint Programme - Neurodegenerative Disease Research</Agency><Country/></Grant><Grant><GrantID>Brainteaser 101017598</GrantID><Agency>Horizon 2020</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">Population-based register</Keyword><Keyword MajorTopicYN="N">Prognostic factor</Keyword><Keyword MajorTopicYN="N">Survival</Keyword><Keyword MajorTopicYN="N">Thyroid disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>24</Day><Hour>23</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36280624</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11426-y</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11426-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Trojsi F, D&#x2019;Alvano G, Bonavita S, Tedeschi G (2020) Genetics and sex in the pathogenesis of amyotrophic lateral sclerosis (ALS): is there a link? Int J Mol Sci 21:3647. https://doi.org/10.3390/ijms21103647</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21103647</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C, Haass C, Edbauer D (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339:1335&#x2013;1338. https://doi.org/10.1126/science.1232927</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Isaacs AM (2018) C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 14:544&#x2013;558. https://doi.org/10.1038/s41582-018-0047-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Suzuki N, Wang JY, Moccia R, Mordes DA, Stewart MH, Suzuki-Uematsu S, Ghosh S, Singh A, Merkle FT, Koszka K, Li QZ, Zon L, Rossi DJ, Trowbridge JJ, Notarangelo LD, Eggan K (2016) Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med 8:347ra93. https://doi.org/10.1126/scitranslmed.aaf6038</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6038</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Y&#xe1;&#xf1;ez A, Lall D, Wolf AJ, Muhammad AK, Ho R, Carmona S, Vit JP, Zarrow J, Kim KJ, Bell S, Harms MB, Miller TM, Dangler CA, Underhill DM, Goodridge HS, Lutz CM, Baloh RH (2016) C9orf72 is required for proper macrophage and microglial function in mice. Science 351:1324&#x2013;1329. https://doi.org/10.1126/science.aaf1064</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1064</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ (2013) Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology 81:1222&#x2013;1225. https://doi.org/10.1212/WNL.0b013e3182a6cc13</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a6cc13</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ZA, Sturm VE, Camsari GB, Karydas A, Yokoyama JS, Grinberg LT, Boxer AL, Rosen HJ, Rankin KP, Gorno-Tempini ML, Coppola G, Geschwind DH, Rademakers R, Seeley WW, Graff-Radford NR, Miller BL (2016) Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: completing the picture. Neurol Neuroimmunol Neuroinflamm 3:e301. https://doi.org/10.1212/NXI.0000000000000301</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000301</ArticleId></ArticleIdList></Reference><Reference><Citation>Katisko K, Solje E, Koivisto AM, Kr&#xfc;ger J, Kinnunen T, Hartikainen P, Helisalmi S, Korhonen V, Herukka SK, Haapasalo A, Remes AM (2018) Prevalence of immunological diseases in a Finnish frontotemporal lobar degeneration cohort with the C9orf72 repeat expansion carriers and non-carriers. J Neuroimmunol 321:29&#x2013;35. https://doi.org/10.1016/j.jneuroim.2018.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2018.05.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredi M, Cavazzana I, Biasiotto G, Filosto M, Padovani A, Monti E, Tincani A, Franceschini F, Zanella I (2019) C9orf72 intermediate alleles in patients with amyotrophic lateral sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. Neuromolecular Med 21:150&#x2013;159. https://doi.org/10.1007/s12017-019-08528-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-019-08528-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Shaw PJ, Kirby J (2014) The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol 127:333&#x2013;345. https://doi.org/10.1007/s00401-014-1251-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1251-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorefice L, Murru MR, Fenu G, Corongiu D, Frau J, Cuccu S, Coghe GC, Tranquilli S, Cocco E, Marrosu MG (2015) A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: the TARDBP Ala382Thr mutation and C9orf72 expansion. J Neurol Sci 357:229&#x2013;34. https://doi.org/10.1016/j.jns.2015.07.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.07.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Wells MF, Limone F, Couto A, Smith KS, Keaney J, Gillet G, van Gastel N, Wang JY, Pietilainen O, Qian M, Eggan P, Cantrell C, Mok J, Kadiu I, Scadden DT, Eggan K (2020) C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature 582:89&#x2013;94. https://doi.org/10.1038/s41586-020-2288-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2288-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Biguzzi S, Guidi C, Venturini E, Sette E, Terlizzi E, Ravasio A, Casmiro M, Salvi F, Liguori R, Rizzi R, Pietrini V, Chierici E, Santangelo M, Granieri E, Mussuto V, Borghi A, Rinaldi R, Fini N, Georgoulopoulou E, De Pasqua S, Vinceti M, Bonvicini F, Ferro S, D&#x2019;Alessandro R, Errals Group (2014) Epidemiology of amyotrophic lateral sclerosis in Emilia Romagna Region (Italy): a population based study. Amyotroph Lateral Scler Frontotemporal Degener 15:262&#x2013;8. https://doi.org/10.1007/s10072-015-2343-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-015-2343-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassano M, Calvo A, Moglia C, Brunetti M, Barberis M, Sbaiz L, Canosa A, Manera U, Vasta R, Corrado L, D&#x2019;Alfonso S, Mazzini L, Scholz SW, Dalgard C, Ding J, Gibbs RJ, Chia R, Traynor BJ, Chi&#xf2; A, Center AG (2021) Mutational analysis of known ALS genes in an Italian population-based cohort. Neurology 96:e600&#x2013;e609. https://doi.org/10.1212/WNL.0000000000011209</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011209</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82:740&#x2013;746. https://doi.org/10.1136/jnnp.2010.235952</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId></ArticleIdList></Reference><Reference><Citation>Manera U, Calvo A, Daviddi M, Canosa A, Vasta R, Torrieri MC, Grassano M, Brunetti M, D&#x2019;Alfonso S, Corrado L, De Marchi F, Moglia C, D&#x2019;Ovidio F, Mora G, Mazzini L, Chi&#xf2; A (2020) Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 91:291&#x2013;297. https://doi.org/10.1136/jnnp-2019-321153</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Biguzzi S, Guidi C, Sette E, Terlizzi E, Ravasio A, Casmiro M, Salvi F, Liguori R, Rizzi R, Pietrini V, Borghi A, Rinaldi R, Fini N, Chierici E, Santangelo M, Granieri E, Mussuto V, De Pasqua S, Georgoulopoulou E, Fasano A, Ferro S, D&#x2019;Alessandro R, ERRALS Group (2015) Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy. Neurol Sci 36:2243&#x2013;52. https://doi.org/10.1007/s10072-015-2343-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-015-2343-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Mazzini L, Cantello R, Mora G, Moglia C, Corrado L, D&#x2019;Alfonso S, Majounie E, Renton A, Pisano F, Ossola I, Brunetti M, Traynor BJ, Restagno G, PARALS (2012) Extensive genetics of ALS: a population-based study in Italy. Neurology 79:1983&#x2013;1989. https://doi.org/10.1212/WNL.0b013e3182735d36</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182735d36</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianferrari G, Martinelli I, Zucchi E, Simonini C, Fini N, Vinceti M, Ferro S, Gessani A, Canali E, Valzania F, Sette E, Pugliatti M, Tugnoli V, Zinno L, Stano S, Santangelo M, De Pasqua S, Terlizzi E, Guidetti D, Medici D, Salvi F, Liguori R, Vacchiano V, Casmiro M, Querzani P, Curr&#xf2; Dossi M, Patuelli A, Morresi S, Longoni M, De Massis P, Rinaldi R, Borghi A, Amedei A, Mandrioli J, Errals Group (2022) Epidemiological, clinical and genetic features of ALS in the last decade: a prospective population-based study in the Emilia Romagna region of Italy. Biomedicines 10:819. https://doi.org/10.3390/biomedicines10040819</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10040819</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Ferri L, Fasano A, Zucchi E, Fini N, Moglia C, Lunetta C, Marinou K, Ticozzi N, Drago Ferrante G, Scialo C, Sorar&#xf9; G, Trojsi F, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Monsurr&#xf2; MR, Sabatelli M, Chi&#xf2; A, Riva N, Logroscino G, Messina S, Calvo A (2018) Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. Eur J Neurol 25:861&#x2013;868. https://doi.org/10.1111/ene.13620</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13620</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, Morrison KE, Petri S, Pradat PF, Silani V, Tomik B, Wasner M, Weber M, EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis (2012) EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)&#x2013;revised report of an EFNS task force. Eur J Neurol 19:360&#x2013;75. https://doi.org/10.1111/j.1468-1331.2011.03501.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano A, Fini N, Ferraro D, Ferri L, Vinceti M, Errals MJ (2017) Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study. Amyotroph Lateral Scler Frontotemporal Degener 18:233&#x2013;242. https://doi.org/10.1080/21678421.2016.1270325</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1270325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Ghiglione P, Mazzini L, Mutani R, Mora G, PARALS (2010) Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy. J Neurol Neurosurg Psychiatry 81:1141&#x2013;1143. https://doi.org/10.1136/jnnp.2009.175984</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.175984</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Al Khleifat A, Fang T, Al-Chalabi A (2019) A standard operating procedure for King&#x2019;s ALS clinical staging. Amyotroph Lateral Scler Frontotemporal Degener 20(3&#x2013;4):159&#x2013;164. https://doi.org/10.1080/21678421.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018</ArticleId></ArticleIdList></Reference><Reference><Citation>Faghri F, Brunn F, Dadu A, Zucchi E, Martinelli I, Mazzini L, Vasta R, Canosa A, Moglia C, Calvo A, Nalls MA, Campbell RH, Mandrioli J, Traynor BJ, Chi&#xf2; A, PARALS consortium; ERRALS consortium (2022) Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study. Lancet Digit Health 4(5):e359&#x2013;e369. https://doi.org/10.1016/S2589-7500(21)00274-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(21)00274-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, Shinoda K, Sugino M, Hanafusa T (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66:265&#x2013;267. https://doi.org/10.1212/01.wnl.0000194316.91908.8a</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId></ArticleIdList></Reference><Reference><Citation>Iazzolino B, Peotta L, Zucchetti JP, Canosa A, Manera U, Vasta R, Grassano M, Palumbo F, Brunetti M, Barberis M, Sbaiz L, Moglia C, Calvo A, Chi&#xf2; A (2021) Differential neuropsychological profile of patients with amyotrophic lateral sclerosis with and without C9orf72 mutation. Neurology 96(1):e141&#x2013;e152. https://doi.org/10.1212/WNL.0000000000011093</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011093</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, Calvo A, Moglia C, Marinou K, Ticozzi N, Drago Ferrante G, Scial&#xf2; C, Sorar&#xf9; G, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Chi&#xf2; A, Mora G, Poletti B, Volanti P, Caponnetto C, Querin G, Sabatelli M, Riva N, Logroscino G, Messina S, Fasano A, Monsurr&#xf2; MR, Tedeschi G, Mandrioli J (2017) Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort. J Neurol 264(11):2224&#x2013;2231. https://doi.org/10.1007/s00415-017-8619-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8619-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, Mioshi E, Roberts-South A, Benatar M, Hortob&#xe1;Gyi T, Rosenfeld J, Silani V, Ince PG, Turner MR (2017) Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 18:153&#x2013;174. https://doi.org/10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinharay S, Stern HS, Russell D (2001) The use of multiple imputation for the analysis of missing data. Psychol Methods 6(4):317&#x2013;329</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/1082-989X.6.4.317</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Boill&#xe9;e S, Le Ber I, Seilhean D, Teyssou E, Giraudeau M, Moigneu C, Vandenberghe N, Danel-Brunaud V, Corcia P, Pradat PF, Le Forestier N, Lacomblez L, Bruneteau G, Camu W, Brice A, Cazeneuve C, Leguern E, Meininger V, Salachas F (2012) Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet 49:258&#x2013;263. https://doi.org/10.1136/jmedgenet-2011-100699</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2011-100699</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, McMillan CT, Brettschneider J, Libon DJ, Powers J, Rascovsky K, Toledo JB, Boller A, Bekisz J, Chandrasekaran K, Wood EM, Shaw LM, Woo JH, Cook PA, Wolk DA, Arnold SE, Van Deerlin VM, McCluskey LF, Elman L, Lee VM, Trojanowski JQ (2013) Grossman M (2013) Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 84:163&#x2013;169. https://doi.org/10.1136/jnnp-2012-303507</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303507</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, Fournier C, Li Y, Polak M, Shaw L, Landers JE, Hu W, Gearing M, Glass JD (2016) Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology 87:1024&#x2013;1030. https://doi.org/10.1212/WNL.0000000000003067</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003067</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, van Veenhuijzen K, van der Spek RA, Peters S, Visser AE, van Rheenen W, Veldink JH, van den Berg LH (2021) Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study. Lancet Neurol 20:373&#x2013;384. https://doi.org/10.1016/S1474-4422(21)00042-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00042-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J, Rich KA, Vicini L, Palettas M, Schroeder J, Zaleski C, Lincoln T, Drury L, Glass JD (2021) Amyotrophic lateral sclerosis genetic access program: paving the way for genetic characterization of ALS in the clinic. Neurol Genet 7(5):e615. https://doi.org/10.1212/NXG.0000000000000615</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000615</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, Calvo A, Moglia C, Marinou K, Ticozzi N, Ferro C, Scial&#xf2; C, Sorar&#xf9; G, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Chi&#xf2; A, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Sabatelli M, Riva N, Logroscino G, Messina S, Fasano A, Monsurr&#xf2; MR, Tedeschi G, Mandrioli J (2019) Comparative analysis of C9orf72 and sporadic disease in a large multicenter ALS population: the effect of male sex on survival of C9orf72 positive patients. Front Neurosci 13:485. https://doi.org/10.3389/fnins.2019.00485</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00485</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasmacher SA, Wong C, Pearson IE, Pal S (2020) Survival and prognostic factors in C9orf72 repeat expansion carriers: a systematic review and meta-analysis. JAMA Neurol 77:367&#x2013;376. https://doi.org/10.1001/jamaneurol.2019.3924</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.3924</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Fogh I, Westeneng HJ, Vajda A, McLaughlin R, Heverin M, Jones A, van Eijk R, Calvo A, Mazzini L, Shaw C, Morrison K, Shaw PJ, Robberecht W, Van Damme P, Al-Chalabi A, van den Berg L, Chi&#xf2; A, Veldink J, Hardiman O (2017) C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 88(4):281. https://doi.org/10.1136/jnnp-2016-314093</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-314093</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, Manera U, D&#x2019;Ovidio F, Vasta R, Grassano M, Brunetti M, Barberis M, Corrado L, D&#x2019;Alfonso S, Iazzolino B, Peotta L, Sarnelli MF, Solara V, Zucchetti JP, De Marchi F, Mazzini L, Mora G, Calvo A (2020) ALS phenotype is influenced by age, sex, and genetics: a population-based study. Neurology 94:e802&#x2013;e810. https://doi.org/10.1212/WNL.0000000000008869</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008869</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C, Calvo A, Grassano M, Canosa A, Manera U, D&#x2019;Ovidio F, Bombaci A, Bersano E, Mazzini L, Mora G, Chi&#xf2; A, Piemonte and Valle d&#x2019;Aosta Register for ALS (PARALS), (2019) Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry 90:666&#x2013;673. https://doi.org/10.1136/jnnp-2018-319611</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319611</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, Ioannides ZA, van Eijk RPA, Heggie S, Thorpe KA, Ceslis A, Heshmat S, Henders AK, Wray NR, van den Berg LH, Henderson RD, McCombe PA, Ngo ST (2018) Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry 89(10):1016&#x2013;1023. https://doi.org/10.1136/jnnp-2017-317887</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollinger SK, Okosun IS, Mitchell CS (2016) Antecedent disease and amyotrophic lateral sclerosis: what is protecting whom? Front Neurol 7:47. https://doi.org/10.3389/fneur.2016.00047</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2016.00047</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S, Hendricks M, Kollewe K, Zapf A, Dengler R, Silani V, Petri S (2013) Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options. BMC Neurol 12(13):84. https://doi.org/10.1186/1471-2377-13-84</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-13-84</ArticleId></ArticleIdList></Reference><Reference><Citation>Matey-Hernandez ML, Williams FMK, Potter T, Valdes AM, Spector TD, Menni C (2018) Genetic and microbiome influence on lipid metabolism and dyslipidemia. Physiol Genomics 50(2):117&#x2013;126. https://doi.org/10.1152/physiolgenomics.00053.2017</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00053.2017</ArticleId></ArticleIdList></Reference><Reference><Citation>Funalot B, Desport JC, Sturtz F, Camu W, Couratier P (2009) High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10(2):113&#x2013;117. https://doi.org/10.1080/17482960802295192</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802295192</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan MM, Taft JA, Reichlin S, Munsat TL (1986) Sustained rises in serum thyrotropin, thyroxine, and triiodothyronine during long term, continuous thyrotropin-releasing hormone treatment in patients with amyotrophic lateral sclerosis. J Clin Endocrinol Metab 63:808&#x2013;814. https://doi.org/10.1210/jcem-63-4-808</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem-63-4-808</ArticleId></ArticleIdList></Reference><Reference><Citation>I&#x142;zecka J, Stelmasiak Z (2003) Thyroid function in patients with amyotrophic lateral sclerosis. Ann Univ Mariae Curie Sklodowska Med 58:343&#x2013;347</Citation></Reference><Reference><Citation>Zheng Z, Guo X, Huang R, Chen X, Shang H (2014) An exploratory study of the association between thyroid hormone and survival of amyotrophic lateral sclerosis. Neurol Sci 35(7):1103&#x2013;1108. https://doi.org/10.1007/s10072-014-1658-z (Epub 2014 Feb 7 PMID: 24504619)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-014-1658-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Paulson JM, Ye FD, Sung M, Hollenberg AN, Rutkove SB (2012) Reducing systemic hypermetabolism by inducing hypothyroidism does not prolong survival in the SOD1-G93A mouse. Amyotroph Lateral Scler 13:372&#x2013;377. https://doi.org/10.3109/17482968.2012.662988</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.662988</ArticleId></ArticleIdList></Reference><Reference><Citation>Hommyo R, Suzuki SO, Abolhassani N, Hamasaki H, Shijo M, Maeda N, Honda H, Nakabeppu Y, Iwaki T (2018) Expression of CRYM in different rat organs during development and its decreased expression in degenerating pyramidal tracts in amyotrophic lateral sclerosis. Neuropathology 38:247&#x2013;259. https://doi.org/10.1111/neup.12466</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12466</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Gal Z, Wang WX, Niedowicz DM, Artiushin SC, Wycoff S, Wei A, Jicha GA, Fardo DW (2019) TDP-43 proteinopathy in aging: Associations with risk-associated gene variants and with brain parenchymal thyroid hormone levels. Neurobiol Dis. 125:67&#x2013;76. https://doi.org/10.1016/j.nbd.2019.01.013 (PMID: 30682540; PMCID: PMC6696921)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.01.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedeene L, Van Schoor E, Ospitalieri S, Ronisz A, Weishaupt JH, Otto M, Ludolph AC, Scheuerle A, Vandenberghe R, Van Damme P, Poesen K, Thal DR (2020) Dipeptide repeat protein and TDP-43 pathology along the hypothalamic-pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases. Acta Neuropathol 140:777&#x2013;781. https://doi.org/10.1007/s00401-020-02216-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02216-9</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>